
Bebtelovimab Treatment – Historical Information
ALL SYMPTOMATIC PATIENTS NEED TO BE SEEN BY A DOCTOR

What Was Bebtelovimab Monoclonal Antibody Treatment?
Bebtelovimab was a monoclonal antibody medication previously authorized by the FDA for certain patients with mild-to-moderate COVID-19 who were at high risk of developing severe illness. It was used in eligible adults and children aged 12 years and older weighing at least 88 pounds (40 kg).
The FDA revoked Bebtelovimab’s Emergency Use Authorization on December 13, 2024. It is no longer authorized for emergency use in the United States.

What Are Monoclonal Antibodies?
- Antibodies are proteins naturally produced by the immune system to help fight infections.
- Monoclonal antibodies (mAbs) are laboratory-made proteins designed to recognize and bind to specific targets, such as proteins on viruses.
- Monoclonal antibodies have been used or studied for various medical conditions, including certain cancers, autoimmune diseases, and infectious diseases.
- Some monoclonal antibody treatments were previously authorized for COVID-19, but their effectiveness against the virus can vary as new variants emerge.
Previous FDA Emergency Use Authorization for Bebtelovimab
Bebtelovimab was granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on February 11, 2022, for certain patients with mild-to-moderate COVID-19 who were at high risk of developing severe illness.
On November 30, 2022, the FDA announced that Bebtelovimab was no longer authorized for use in any U.S. region because circulating COVID-19 variants were not expected to respond to the treatment.
The FDA formally revoked Bebtelovimab’s Emergency Use Authorization on December 13, 2024. Bebtelovimab is no longer authorized for emergency use in the United States.
This information is provided for historical and educational purposes only.
Who Was Previously Eligible for Bebtelovimab Treatment?
Bebtelovimab was previously authorized by the U.S. Food and Drug Administration (FDA) to treat certain patients with mild-to-moderate COVID-19 who were at high risk of developing severe illness. Under its former Emergency Use Authorization (EUA), patients generally needed to meet the following criteria:
- Confirmed COVID-19 Infection: A positive SARS-CoV-2 viral test result.
- High Risk of Severe Illness: An increased risk of developing severe COVID-19, including hospitalization or death.
- Limited Treatment Alternatives: Other FDA-approved or authorized COVID-19 treatments were unavailable or clinically inappropriate.
Important Update: The FDA revoked Bebtelovimab’s Emergency Use Authorization on December 13, 2024. Bebtelovimab is no longer authorized for emergency use in the United States. These eligibility criteria are provided for historical and educational purposes only.
Previously Reported Side Effects of Bebtelovimab
During its previous use, Bebtelovimab was associated with potential side effects, including allergic reactions and reactions at the injection site.
Reported symptoms of allergic reactions included rash, itching, swelling, breathing difficulties, dizziness, and changes in blood pressure. Serious allergic reactions could occur.
Administration-related effects could include temporary pain, bruising, swelling, or soreness at the injection site.
Bebtelovimab is no longer authorized for emergency use in the United States. This information is provided for historical and educational purposes only.
